Investigational Drug Information for CC-90001
✉ Email this page to a colleague
What is the drug development status for CC-90001?
CC-90001 is an investigational drug.
There have been 10 clinical trials for CC-90001.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 26th 2017.
The most common disease conditions in clinical trials are Fibrosis, Pulmonary Fibrosis, and Liver Diseases. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.
Summary for CC-90001
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 49 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 1 (2017-07-26) |
| Vendors | 12 |
Recent Clinical Trials for CC-90001
| Title | Sponsor | Phase |
|---|---|---|
| A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Bristol-Myers Squibb | Phase 1 |
| Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects | Celgene | Phase 1 |
| Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis | Celgene | Phase 2 |
Clinical Trial Summary for CC-90001
Top disease conditions for CC-90001
Top clinical trial sponsors for CC-90001
US Patents for CC-90001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
